Table 4

Estimated changes in lung cancer mortality following the launch of targeted therapies (gefitinib and erlotinib) using interrupted time series and segmented regression models

InterceptBaseline trend
(95% CI)
Changes after the launch of gefitinib (2003)Changes after the launch of gefitinib and erlotinib (2006)
Level change
(95% CI)
Trend change
(95% CI)
Absolute change
(3 years later)
(95% CI)
Relative change
(3 years later)
(95% CI)
Level change
(95% CI)
Trend change
(95% CI)
Absolute change
(3 years later)
(95% CI)
Relative change
(3 years later)
(95% CI)
Mortality (all)25.750.26
(0.11 to 0.42)
NS−0.58
(−0.81 to −0.34)
−1.73
(−2.43 to −1.02)
−5.97%
(−8.20% to −3.73%)
NSNS00.00%
Mortality (male)34.480.45
(0.20 to 0.70)
−2.15
(−4.11 to −0.20)
NS−2.15
(−4.11 to −0.20)
−5.40%
(−10.08% to −0.73%)
NS−0.94
(−1.29 to −0.59)
−2.81
(−3.87 to −1.76)
−7.20%
(−9.69% to −4.71%)
Mortality (female)15.800.17
(0.04 to 0.30)
NS−0.26
(−0.46 to −0.06)
−0.78
(−1.38 to −0.19)
−4.38%
(−7.50% to −1.25%)
NSNS00.00%
  • 95% CI=estimate±(1.96*SE); all terms p<0.1 retained in models.

  • CI, confidence interval; NS, non-significant; SE, standard error.